Valsamo Anagnostou

List of Publications by Year in descending order

54 papers	8,883 citations	156536 32 h-index	242451 47 g-index
57 all docs	57 docs citations	57 times ranked	16339 citing authors

#	Article	IF	Citations
1	Genetic variation in antigen presentation and cancer immunotherapy. Immunity, 2022, 55, 3-6.	6.6	5
2	An Evaluation of Pretrained BERT Models for Comparing Semantic Similarity Across Unstructured Clinical Trial Texts. Studies in Health Technology and Informatics, 2022, 289, 18-21.	0.2	4
3	Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesotheliomaâ€"a phase 3 randomised trial. BMJ Open, 2022, 12, e057663.	0.8	9
4	Multicenter phase II study of neoadjuvant nivolumab or nivolumab plus relatlimab (anti-LAG3) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 carcinoma.. Journal of Clinical Oncology, 2022, 40, 321-321.	0.8	5
5	Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets. Clinical Cancer Research, 2022, 28, 2361-2372.	3.2	2
6	Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. , 2022, 10, e004688.		34
7	Multicenter phase II study of abemaciclib and ramucirumab in metastatic esophageal/gastroesophageal junction carcinoma.. Journal of Clinical Oncology, 2022, 40, TPS4169-TPS4169.	0.8	0
8	DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesotheliomaâ€"A phase 3 randomized trial.. Journal of Clinical Oncology, 2022, 40, TPS8599-TPS8599.	0.8	0
9	Association of High Tumor Mutation Burden in Nonâ€"Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 2022, 8, 1160.	3.4	117
10	The status of tumor mutational burden and immunotherapy. Nature Cancer, 2022, 3, 652-656.	5.7	48
11	Natural Language Processing Approaches for Retrieval of Clinically Relevant Genomic Information in Cancer. Studies in Health Technology and Informatics, 2022, , .	0.2	0
12	Translating noninvasive molecular responses into clinical reality for cancer immunotherapy. Nature Reviews Clinical Oncology, 2021, 18, 65-66.	12.5	9
13	Immunogenomic features of pathologic response to neoadjuvant immune checkpoint blockade in esophageal cancer.. Journal of Clinical Oncology, 2021, 39, 4042-4042.	0.8	0
14	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature, 2021, 596, 126-132.	13.7	234
15	Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nature Communications, 2021, 12, 5060.	5.8	161
16	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature Medicine, 2021, 27, 1910-1920.	15.2	62
17	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature Cancer, 2020, 1, 99-111.	5.7	141
18	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Reports Medicine, 2020, 1, 100139.	3.3	45

#	Article	IF	Citations
19	Conserved Interferon-Î³ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 2020, 38, 500-515.e3.	7.7	203
20	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108
21	High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets. Cancer Immunology Research, 2020, 8, 396-408.	1.6	103
22	Visual storytelling enhances knowledge dissemination in biomedical science. Journal of Biomedical Informatics, 2020, 107, 103458.	2.5	14
23	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nature Communications, 2020, 11, 525.	5.8	158
24	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	3.2	90
25	Comprehensive modeling of longitudinal circulating tumor DNA dynamics to predict clinical response to first-line immunotherapy and chemoimmunotherapy in advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, 9525-9525.	0.8	1
26	Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 2019, 570, 385-389.	13.7	764
27	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
28	Early Noninvasive Detection of Response to Targeted Therapy in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2019, 79, 1204-1213.	0.4	75
29	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2019, 79, 1214-1225.	0.4	226
30	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. Journal of Clinical Investigation, 2019, 129, 4305-4315.	3.9	100
31	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	13.9	1,495
32	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 2018, 9, 28561-28571.	0.8	129
33	A machine learning approach for somatic mutation discovery. Science Translational Medicine, 2018, 10, .	5.8	80
34	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunology Research, 2018, 6, 888-899.	1.6	118
35	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2017, 7, 264-276.	7.7	706
36	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. Clinical Cancer Research, 2017, 23, 4959-4969.	3.2	115

#	Article	IF	Citations
37	Direct detection of early-stage cancers using circulating tumor DNA. Science Translational Medicine, 2017, 9, .	5.8	808
38	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell, 2017, 171, 1284-1300.e21.	13.5	366
39	Primary parotid adenocarcinoma metastasis to the spleen with mutation: cytological findings and review of the literature. International Journal of Clinical and Experimental Pathology, 2017, 10, 5999-6005.	0.5	2
40	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications, 2015, 6, 7686.	5.8	393
41	Personalized genomic analyses for cancer mutation discovery and interpretation. Science Translational Medicine, 2015, 7, 283ra53.	5.8	347
42	The genomic landscape of response to EGFR blockade in colorectal cancer. Nature, 2015, 526, 263-267.	13.7	398
43	Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. Laboratory Investigation, 2015, 95, 334-341.	1.7	52
44	A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Laboratory Investigation, 2014, 94, 467-474.	1.7	48
45	Measurement of Aldehyde Dehydrogenase 1 Expression Defines a Group with Better Prognosis in Patients with Non-Small Cell Lung Cancer. American Journal of Pathology, 2012, 181, 1436-1442.	1.9	41
46	Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells. PLoS ONE, 2012, 7, e31331.	1.1	55
47	Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Nonâ€“Small Cell Lung Cancer. American Journal of Pathology, 2011, 179, 580-589.	1.9	21
48	Antibody validation. BioTechniques, 2010, 48, 197-209.	0.8	548
49	Developing a multivariable prognostic model for pancreatic endocrine tumors using the clinical data warehouse resources of a single institution. Applied Clinical Informatics, 2010, 01, 38-49.	0.8	6
50	Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Research and Treatment, 2009, 115, 77-85.	1.1	45
51	GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature, 2009, 459, 1085-1090.	13.7	311
52	Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. Anticancer Research, 2008, 28, 1411-5.	0.5	11
53	Epithelioid haemangioendothelioma of the lung presenting with pulmonary nocardiosis. In Vivo, 2007, 21, 1123-6.	0.6	4
54	Ontogeny of intrinsic innervation in the human kidney. Anatomy and Embryology, 2004, 209, 41-47.	1.5	17